Can UCB’s $2.2bn Candid Therapeutics deal reset the future of autoimmune therapy?
UCB is paying heavily for early autoimmune science. Candid tests whether T-cell engagers can move beyond oncology into immune reset.
How Imviva Biotech is positioning allogeneic CAR-T therapy for autoimmune disease disruption
Can CTA313 redefine lupus treatment with CAR-T? Explore what Imviva Biotech’s early data means for autoimmune therapy innovation.
Tempest Therapeutics, Inc. bets on dual-targeting CAR-T to address antigen escape challenges
Tempest Therapeutics, Inc. advances TPST-2003 CAR-T data. Discover how dual-targeting could impact multiple myeloma treatment durability.
What Tempest Therapeutics, Inc.’s CAR-T strategy reveals about the next phase of cell therapy competition
Find out how Tempest Therapeutics, Inc.’s CAR-T strategy could shape the next phase of cell therapy competition and multiple myeloma innovation.
Why Innovent Biologics’ tri-specific IBI3055 matters in the race to deplete both B cells and plasma cells
Innovent Biologics unveiled preclinical IBI3055 data in autoimmune disease. Read what this could change for immune-reset therapies.
Gilead targets durable autoimmune remission with $2.18bn Ouro Medicines acquisition
Gilead Sciences acquires Ouro Medicines for up to $2.18bn, adding BCMA T cell engager gamgertamig to its inflammation pipeline. Analysis of what the deal reveals.
J&J’s Tecvayli-Darzalex Faspro combination approved for myeloma after MajesTEC-3 Phase 3 results
FDA approves J&J’s teclistamab plus daratumumab for relapsed myeloma from second line. Analyse the MajesTEC-3 data, safety profile, and what this changes for treatment.
Can Vyriad’s VV169 redefine CAR T therapy with single-dose in vivo delivery?
Vyriad secures $85M to launch VV169, its in vivo CAR T therapy for multiple myeloma. Find out how this platform could reshape cancer immunotherapy.